STOCK TITAN
  1. Home
  2. News
  3. OCS

Oculis Holding AG Ordinary shares - OCS STOCK NEWS

Welcome to our dedicated page for Oculis Holding Ordinary shares news (Ticker: OCS), a resource for investors and traders seeking the latest updates and insights on Oculis Holding Ordinary shares stock.

Oculis Holding AG (Nasdaq: OCS) is a leading global biopharmaceutical company dedicated to saving sight and enhancing eye care. Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is at the forefront of developing innovative treatments for serious eye diseases. The company's pipeline includes several promising candidates:

  • OCS-01: A topical eye drop for diabetic macular edema (DME) and post-cataract surgery inflammation and pain. OCS-01 has shown compelling Phase 3 data, making it a potential new standard of care for these conditions.
  • OCS-02: A topical biologic anti-TNFα eye drop for dry eye disease (DED) and non-infectious anterior uveitis. The OCS-02 RELIEF trial is in Phase 2b, with results eagerly anticipated.
  • OCS-05: A neuroprotective candidate for acute optic neuritis (AON) and other neuro-ophthalmic disorders such as glaucoma and diabetic retinopathy. The ACUITY trial is set to provide critical data by the end of the year.

Oculis recently announced its fourth-quarter and full-year 2023 financial results, highlighted by positive Phase 3 data for OCS-01 and the commencement of three clinical trials, including OCS-02's RELIEF trial. The company is on track for a catalyst-rich 2024 with significant upcoming milestones, including readouts from the RELIEF trial in Q2 and the OPTIMIZE-2 and ACUITY trials in Q4. These milestones are crucial for Oculis' plan to submit its first New Drug Application (NDA).

Under the leadership of CEO Riad Sherif, M.D., Oculis has achieved remarkable progress and continues to advance its diversified pipeline. The company is backed by leading international healthcare investors and boasts a seasoned management team with a strong track record of success.

Financially, Oculis has reported significant strides, supported by both new and existing investors. The company has dual listings on Nasdaq in the U.S. and Iceland, reflecting its robust financial health and market confidence.

For more information, please visit Oculis Holding AG's website. For investor and media inquiries, contact Ms. Sylvia Cheung, CFO at sylvia.cheung@oculis.com or Corey Davis, Ph.D. at LifeSci Advisors at cdavis@lifesciadvisors.com.

News

Oculis Publishes Invitation to the Annual General Meeting

Rhea-AI Summary

Oculis Holding AG has published an invitation to its 2024 Annual General Meeting to be held on May 29, 2024, in Zug, Switzerland. The meeting details and materials are available on the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.67%
Tags
none
-
News

Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market

Rhea-AI Summary
Oculis Holding AG announced the closing of a registered direct offering, raising $59 million through the sale of 5,000,000 ordinary shares at $11.75 per share. The company will commence trading on the Nasdaq Iceland Main Market under the symbol 'OCS' on April 23, 2024, becoming the second company dual-listed on NASDAQ U.S. and NASDAQ Iceland. The Phase 2b RELIEF trial of OCS-02 in Dry Eye Disease remains on track for a readout in Q2 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
offering
-
News

Oculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main Market

Rhea-AI Summary
Oculis Holding AG completes a $59 million financing, extends cash runway until 2H 2026. The company plans to list its ordinary shares on the Nasdaq Iceland Main Market under the ticker symbol 'OCS'. Oculis aims to report topline data from OCS-02 Phase 2b RELIEF trial in Dry Eye Disease in Q2 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.65%
Tags
offering
News

Oculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as President of Research & Development

Rhea-AI Summary
Oculis Holding AG (Nasdaq: OCS) appoints Dr. Snehal Shah as President of R&D, expanding its executive leadership team. Dr. Shah brings over two decades of experience in drug development and regulatory affairs, with a successful track record in market approvals. Oculis aims to advance its late-stage pipeline and prepare for global marketing applications, including its first NDA submission to the U.S. FDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.18%
Tags
management
-
News

Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting

Rhea-AI Summary
Oculis Holding AG (Nasdaq: OCS) presented positive results from the Phase 3 OPTIMIZE-1 trial of OCS-01 for treating inflammation and pain after cataract surgery at the 2024 ASCRS Annual Meeting. The results showed significant improvement in treating inflammation and pain compared to the vehicle. OCS-01, a preservative-free corticosteroid, aims to be the first once-daily eye drop treatment for various eye conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.58%
Tags
clinical trial
-
News

Oculis to Participate at Upcoming April Investor Conferences

Rhea-AI Summary
Oculis Holding AG (Nasdaq: OCS) announces its participation in upcoming investor conferences to present its corporate overview and engage with potential investors. The management will attend the Needham Annual Virtual Healthcare Conference on April 11, 2024, and the Van Lanschot Kempen Life Sciences Conference on April 16-17, 2024, in Amsterdam. Investors can schedule one-on-one meetings to learn more about Oculis's vision and strategic direction in the biopharmaceutical industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.15%
Tags
conferences
News

Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress

Rhea-AI Summary
Oculis Holding AG (Nasdaq: OCS) reports a successful year with positive Phase 3 results in OCS-01 for Diabetic Macular Edema and inflammation following cataract surgery. The company plans to release data from OCS-02 Phase 2b RELIEF trial in Dry Eye Disease in Q2 2024 and OCS-01 Phase 3 OPTIMIZE-2 trial in Q4 2024. Financially, Oculis has $108.9 million in cash and short-term investments, with a focus on advancing key programs and clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.22%
Tags
earnings
-
News

Oculis Provides Updates at R&D Day on Late-Stage Clinical Trials and Announces Key Leadership Appointments

Rhea-AI Summary
Oculis Holding AG (Nasdaq: OCS) provides updates on its late-stage clinical trials and management appointments. The company completed enrollment in the Phase 2b RELIEF trial of OCS-02 for Dry Eye Disease, initiated the DIAMOND-2 Phase 3 trial for Diabetic Macular Edema, and made key executive appointments. Topline results for the RELIEF trial are expected in Q2 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.41%
Tags
clinical trial
-
News

Oculis to Present at Upcoming February Investor Conferences

Rhea-AI Summary
Oculis Holding AG (Nasdaq: OCS) announced its participation in upcoming investor conferences, including the Stifel Biotech Executive Summit and BioCapital Europe 2024. The company's CEO and CFO will be presenting at these events, providing an opportunity for interested investors to engage with Oculis' management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.58%
Tags
conferences
News

Oculis to Host In-Person & Virtual R&D Day in New York on February 28, 2024

Rhea-AI Summary
Oculis Holding AG (Nasdaq: OCS) announced an in-person R&D Day in New York City to showcase two clinical programs: OCS-01, a high concentration dexamethasone eye drop formulation for Diabetic Macular Edema, and OCS-02, a TNFα inhibitor licaminlimab eye drop formulation for Dry Eye Disease. The event will feature presentations from renowned medical professionals and provide a 2023 review and business outlook for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.84%
Tags
conferences

FAQ

What is the current stock price of Oculis Holding Ordinary shares (OCS)?

The current stock price of Oculis Holding Ordinary shares (OCS) is $17.65 as of January 6, 2025.

What is the market cap of Oculis Holding Ordinary shares (OCS)?

The market cap of Oculis Holding Ordinary shares (OCS) is approximately 738.2M.

What is Oculis Holding AG?

Oculis Holding AG is a global biopharmaceutical company focused on developing treatments for serious eye diseases, including diabetic macular edema and dry eye disease.

What products are in Oculis' pipeline?

Oculis' pipeline includes OCS-01 for diabetic macular edema, OCS-02 for dry eye disease, and OCS-05 for acute optic neuritis and other neuro-ophthalmic disorders.

Where is Oculis headquartered?

Oculis is headquartered in Switzerland, with additional operations in the U.S. and Iceland.

What recent achievements has Oculis made?

In 2023, Oculis had positive Phase 3 results for OCS-01 and initiated three clinical trials, including the OCS-02 Phase 2b RELIEF trial for dry eye disease.

Who leads Oculis Holding AG?

Oculis is led by CEO Riad Sherif, M.D., alongside an experienced management team with a successful track record and support from leading international healthcare investors.

What are the upcoming milestones for Oculis in 2024?

Upcoming milestones include the RELIEF trial readout for OCS-02 in Q2, and Phase 3 readouts for OCS-01 and OCS-05 in Q4, along with the submission of the first NDA.

How did Oculis perform financially in 2023?

Oculis reported strong financial results for 2023, supported by significant investor backing and a successful dual listing on Nasdaq in the U.S. and Iceland.

What conditions does OCS-01 treat?

OCS-01 is a topical eye drop candidate for treating diabetic macular edema (DME) and for post-cataract surgery inflammation and pain.

What is the OCS-02 RELIEF trial?

The OCS-02 RELIEF trial is a Phase 2b clinical study evaluating the efficacy of OCS-02, a topical biologic anti-TNFα eye drop, for treating dry eye disease (DED).

How can I contact Oculis for investor or media inquiries?

For inquiries, you can contact CFO Sylvia Cheung at sylvia.cheung@oculis.com or Corey Davis, Ph.D., at cdavis@lifesciadvisors.com.
Stock OCS logo
Oculis Holding AG Ordinary shares

Nasdaq:OCS

OCS Rankings

#2810 Ranked by Market Cap
N/A Ranked by Dividends

OCS Stock Data

738.23M
38.93M
7.23%
32.21%
0.05%
Biotechnology
Healthcare
Link
United States of America
Zug